Eli Lilly and Company (LLY) Position Maintained by BerganKDV Wealth Management LLC
BerganKDV Wealth Management LLC continued to hold its position in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,403 shares of the company’s stock at the end of the first quarter. BerganKDV Wealth Management LLC’s holdings in Eli Lilly and were worth $324,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Mutual of America Capital Management LLC raised its position in shares of Eli Lilly and by 1.6% in the first quarter. Mutual of America Capital Management LLC now owns 117,125 shares of the company’s stock worth $9,851,000 after buying an additional 1,809 shares during the period. Holderness Investments Co. acquired a new position in shares of Eli Lilly and during the first quarter worth about $228,000. Financial Advisory Service Inc. raised its position in Eli Lilly and by 1.7% in the first quarter. Financial Advisory Service Inc. now owns 6,084 shares of the company’s stock worth $512,000 after buying an additional 103 shares during the period. State of Tennessee Treasury Department raised its position in Eli Lilly and by 13.3% in the first quarter. State of Tennessee Treasury Department now owns 1,222,822 shares of the company’s stock worth $102,852,000 after buying an additional 143,357 shares during the period. Finally, Jaffetilchin Investment Partners LLC purchased a new position in Eli Lilly and during the first quarter worth $667,000. Institutional investors and hedge funds own 75.48% of the company’s stock.
Eli Lilly and Company (NYSE:LLY) traded up 0.46% on Friday, hitting $82.31. The stock had a trading volume of 2,802,600 shares. The stock has a 50-day moving average of $82.99 and a 200-day moving average of $81.53. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The company has a market cap of $86.84 billion, a PE ratio of 35.62 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter last year, the business posted $0.86 earnings per share. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Equities analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Friday, August 11th. This represents a $2.08 annualized dividend and a yield of 2.53%. Eli Lilly and’s dividend payout ratio is currently 90.04%.
COPYRIGHT VIOLATION WARNING: “Eli Lilly and Company (LLY) Position Maintained by BerganKDV Wealth Management LLC” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/04/eli-lilly-and-company-lly-position-maintained-by-bergankdv-wealth-management-llc-updated-updated-updated.html.
LLY has been the topic of a number of analyst reports. Citigroup Inc. reiterated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a research report on Thursday, April 6th. Barclays PLC lifted their price objective on shares of Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, April 7th. Jefferies Group LLC reiterated a “buy” rating and issued a $97.00 price objective on shares of Eli Lilly and in a research report on Monday, April 10th. Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Tuesday, April 11th. Finally, BMO Capital Markets lowered shares of Eli Lilly and from a “market perform” rating to an “underperform” rating and lowered their price objective for the company from $73.00 to $71.00 in a research report on Monday, April 17th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $88.37.
In other news, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the sale, the vice president now directly owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the sale, the insider now directly owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders have sold 669,733 shares of company stock valued at $55,845,287 in the last ninety days. Company insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.